Articles related to ANAPHYLAXIS/ALLERGIC REACTIONS

The FDA expanded the indication for olopatadine hydrochloride and mometasone furoate nasal spray to include children aged 6 to younger than 12 years with seasonal allergic rhinitis. Approval was supported by a phase 3 trial demonstrating improved nasal symptoms versus placebo.

A retrospective study of 606 pediatric patients found serum specific IgE testing for allergic rhinitis was frequently negative in children younger than 3 years and became more informative with age. Findings may aid diagnostic decision-making, though prospective validation is needed.

“This device will become many patients’ primary epinephrine device because it removes the hurdle to administering epinephrine earlier in the anaphylactic process.” — Haley Overstreet, MD, Aspire Allergy & Sinus

The hospital allegedly lacked a pediatric mask and breathing tubes, delaying life-saving care during an anaphylactic emergency.

Neffy 1mg expands access to emergency epinephrine for children under 30 kg, with a user-friendly nasal spray format and broad affordability programs.

Nonantimicrobial sulfonamides lack an arylamine group at the N4 position, so they do not cross-react with antimicrobial sulfonamides.